DiaMedica Announces Continuance Under the Canada Business Corporations Act

MINNEAPOLIS, MINNESOTA--(Marketwired - April 18, 2016) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), is pleased to announce that, effective April 11, 2016, it has been continued as a federal corporation subject to the provisions of the Canada Business Corporations Act. The continuance was approved by the shareholders of the Company at the Company's Annual General and Special Meeting of shareholders held on October 23, 2015.

About DiaMedica

DiaMedica is a publicly traded clinical stage biopharmaceutical company focused on developing novel treatments for vascular diseases, including stroke and metabolic and kidney dysfunction. DiaMedica's common shares are listed on the TSX Venture Exchange under the trading symbol "DMA" and on the OTCQB under the trading symbol "DMCAF".

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.